Kronos Bio Statistics
Total Valuation
Kronos Bio has a market cap or net worth of $59.85 million. The enterprise value is -$87.71 million.
| Market Cap | 59.85M |
| Enterprise Value | -87.71M |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Kronos Bio has 60.10 million shares outstanding. The number of shares has increased by 2.75% in one year.
| Shares Outstanding | 60.10M |
| Shares Change (YoY) | +2.75% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 19.59% |
| Owned by Institutions (%) | 44.68% |
| Float | 43.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.39 |
| Forward PS | 9.70 |
| PB Ratio | 0.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.24, with a Debt / Equity ratio of 0.18.
| Current Ratio | 7.24 |
| Quick Ratio | n/a |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -58.80% and return on invested capital (ROIC) is -65.03%.
| Return on Equity (ROE) | -58.80% |
| Return on Assets (ROA) | -45.00% |
| Return on Capital (ROIC) | -65.03% |
| Revenue Per Employee | $101,419 |
| Profits Per Employee | -$1.82M |
| Employee Count | 62 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.32% in the last 52 weeks. The beta is 1.83, so Kronos Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.83 |
| 52-Week Price Change | -26.32% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 36.27 |
| Average Volume (30 Days) | 375,182 |
Short Selling Information
The latest short interest is 662,733, so 1.10% of the outstanding shares have been sold short.
| Short Interest | 662,733 |
| Short Previous Month | 665,007 |
| Short % of Shares Out | 1.10% |
| Short % of Float | 1.51% |
| Short Ratio (days to cover) | 3.47 |
Income Statement
In the last 12 months, Kronos Bio had revenue of $6.29 million and -$112.67 million in losses. Loss per share was -$1.95.
| Revenue | 6.29M |
| Gross Profit | 6.29M |
| Operating Income | -121.83M |
| Pretax Income | -112.67M |
| Net Income | -112.67M |
| EBITDA | -107.76M |
| EBIT | -112.67M |
| Loss Per Share | -$1.95 |
Balance Sheet
The company has $175.02 million in cash and $28.27 million in debt, giving a net cash position of $146.75 million or $2.44 per share.
| Cash & Cash Equivalents | 175.02M |
| Total Debt | 28.27M |
| Net Cash | 146.75M |
| Net Cash Per Share | $2.44 |
| Equity / Book Value | 159.08M |
| Book Value Per Share | 2.65 |
| Working Capital | 154.08M |
Cash Flow
In the last 12 months, operating cash flow was -$78.58 million and capital expenditures -$679,000, giving a free cash flow of -$79.26 million.
| Operating Cash Flow | -78.58M |
| Capital Expenditures | -679,000 |
| Free Cash Flow | -79.26M |
| FCF Per Share | -$1.37 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,937.50% and -1,791.87%.
| Gross Margin | 100.00% |
| Operating Margin | -1,937.50% |
| Pretax Margin | -1,791.87% |
| Profit Margin | -1,791.87% |
| EBITDA Margin | -1,713.69% |
| EBIT Margin | -1,791.87% |
| FCF Margin | -1,260.51% |
Dividends & Yields
Kronos Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.75% |
| Shareholder Yield | -2.75% |
| Earnings Yield | -190.83% |
| FCF Yield | -134.24% |
Analyst Forecast
The average price target for Kronos Bio is $4.25, which is 320.79% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.25 |
| Price Target Difference | 320.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 142.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kronos Bio has an Altman Z-Score of -3.53 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.53 |
| Piotroski F-Score | 2 |